Disease · MONDO_0005469
orthostatic hypotension
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. orthostatic hypotension. Diseases, record MONDO_0005469. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005469
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- orthostatic hypotension
- Open Targets ID
- MONDO_0005469
- Other names
- orthostatic hypotension (disease), postural hypotension
- Highest stage of its drugs
- Approval, for 4 of its 42 drugs, from ClinicalTrials.gov, DailyMed and TTD
Source Open Targets
Drugs42
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DROXIDOPA | CHEMBL2103827 | Small molecule | Approval | ClinicalTrials.gov and DailyMed | 11 | 10 | 10 | Drugs and targets |
| MIDODRINE | CHEMBL1201212 | Small molecule | Approval | TTD | 7 | 6 | 6 | Drugs and targets |
| CAFFEINE | CHEMBL113 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| OXILOFRINE | CHEMBL30400 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| MIDODRINE HYDROCHLORIDE | CHEMBL1200461 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| HUMAN IMMUNOGLOBULIN G | CHEMBL1201599 | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets | |
| METHYLPREDNISOLONE | CHEMBL650 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PYRIDOSTIGMINE | CHEMBL1115 | Small molecule | Phase 2 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| ATOMOXETINE | CHEMBL641 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| IVABRADINE | CHEMBL471737 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 42
See all 42 drugsTargets43
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRA1A | Adrenergic receptor | 6 | Adrenergic receptor agonist; Adrenergic receptor alpha agonist; Adrenergic receptor alpha-1 agonist | Approval | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor | 6 | Adrenergic receptor agonist; Adrenergic receptor alpha agonist; Adrenergic receptor alpha-1 agonist | Approval | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor | 6 | Adrenergic receptor agonist; Adrenergic receptor alpha agonist; Adrenergic receptor alpha-1 agonist | Approval | https://conductscience.org/library/genes/146 | Drugs and targets |
| ADRA2A | Adrenergic receptor | 5 | Adrenergic receptor agonist; Adrenergic receptor alpha agonist; Adrenergic receptor alpha-2 antagonist | Approval | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor | 5 | Adrenergic receptor agonist; Adrenergic receptor alpha agonist; Adrenergic receptor alpha-2 antagonist | Approval | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor | 5 | Adrenergic receptor agonist; Adrenergic receptor alpha agonist; Adrenergic receptor alpha-2 antagonist | Approval | https://conductscience.org/library/genes/152 | Drugs and targets |
| ACHE | Acetylcholinesterase | 4 | Acetylcholinesterase inhibitor; Cholinesterases; ACHE & BCHE inhibitor | Phase 2 | https://conductscience.org/library/genes/43 | Drugs and targets |
| SLC6A2 | Sodium-dependent noradrenaline transporter | 4 | Norepinephrine transporter inhibitor; Norepinephrine transporter releasing agent | Phase 2 | https://conductscience.org/library/genes/6530 | Drugs and targets |
| ADRB1 | Adrenergic receptor | 3 | Adrenergic receptor agonist; Beta-1 adrenergic receptor antagonist | Approval | https://conductscience.org/library/genes/153 | Drugs and targets |
| ADRB2 | Adrenergic receptor | 3 | Adrenergic receptor agonist; Beta-2 adrenergic receptor antagonist | Approval | https://conductscience.org/library/genes/154 | Drugs and targets |
1 to 10 of 43
See all 43 targetsTrials35
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01132326 | Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304) | Phase 3 | 350 | 2014-04-21 | Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency, Non-Diabetic Neuropathy, Neurogenic Orthostatic Hypotension | DROXIDOPA | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00738062 | Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) | Phase 3 | 103 | 2014-05-16 | Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy, Multiple System Atrophy, Dopamine Beta Hydroxylase Deficiency | DROXIDOPA | Its record names the disease | ClinicalTrials.gov |
| NCT02919917 | Treatment of Post-SCI Hypotension | Phase 2/3 | 66 | 2025-02-21 | Spinal Cord Injury, Autonomic Dysreflexia, Orthostatic Hypotension, Baroreceptor Integrity, Sympathetic Integrity, Vagal Integrity, Hypotension, Cerebral Blood Flow, Blood Pressure, Venous Occlusion Plethysmography | MIDODRINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02784535 | Norepinephrine Transporter Blockade, Autonomic Failure (NETAF) | Phase 2 | 48 | 2022-09-16 | Neurogenic Orthostatic Hypotension | ATOMOXETINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02705755 | TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) | Phase 2 | 34 | 2022-09-26 | Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure, Parkinson Disease, Hypotension, Orthostatic, Orthostatic Hypotension, Pure Autonomic Failure With Orthostatic Hypotension, Parkinson Disease With Orthostatic Hypotension | AMPRELOXETINE | Its record names the disease | ClinicalTrials.gov |
| NCT03919773 | IVIG (Gamunex-C) Treatment Study for POTS Subjects | Phase 1/2 | 30 | 2024-09-19 | Postural Tachycardia Syndrome | ALBUMIN HUMAN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02893553 | The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury | Phase 2 | 21 | 2024-10-01 | Spinal Cord Injury, Autonomic Dysreflexia, Baroreceptor Integrity, Sympathetic Integrity, Vagal Integrity, Autonomic Integrity, Hypotensive, Cognitive Function, Cerebral Blood Flow, Blood Pressure | MIDODRINE HYDROCHLORIDE, MIRABEGRON, PYRIDOSTIGMINE BROMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00547911 | Augmenting Effects of L-DOPS With Carbidopa and Entacapone | Phase 1/2 | 14 | 2014-07-17 | Parkinson Disease, Multiple System Atrophy, Autonomic Nervous System Diseases | CARBIDOPA, DROXIDOPA, ENTACAPONE | Its record names the disease | ClinicalTrials.gov |
| NCT02154243 | An Open Label Trial to Decrease Signs and Symptoms of Orthostatic Hypotension Using Midodrine or Intravenous Fluid Bolus in Patients Following Total Hip Arthroplasty | Not applicable | 13 | 2017-07-31 | Orthostatic Hypotension | MIDODRINE | Its record names the disease | ClinicalTrials.gov |
| NCT00426842 | A Dose Response Trial Using 5 and 10 Mg of Midodrine Hydrochloride | Phase 2 | 11 | 2015-05-12 | Orthostatic Hypotension, Spinal Cord Injury | MIDODRINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 35
See all 35 trialsComparisons in its trials6
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| BP Threshold Treatment Group vs Usual Care Group: deaths from any cause | 0 of 25 | 0 of 29 | 54 | NCT02919917 | Trial comparisons |
| BP Threshold Treatment Group vs Usual Care Group: serious adverse events | 0 of 25 | 0 of 29 | 54 | NCT02919917 | Trial comparisons |
| Treatment IVIG Arm vs Treatment Albumin Arm: deaths from any cause | 0 of 28 | 0 of 26 | 54 | NCT03919773 | Trial comparisons |
| Treatment IVIG Arm vs Treatment Albumin Arm: serious adverse events | 2 of 28 | 2 of 26 | 54 | NCT03919773 | Trial comparisons |
| Treatment IVIG Arm vs Treatment Albumin Arm: Number of Participants With Clinical Improvement | 7 of 15 | 5 of 13 | 28 | NCT03919773 | Trial comparisons |
| Day 1 - No Drug vs Day 2 - Pyridostigmine Bromide: serious adverse events | 0 of 10 | 2 of 10 | 20 | NCT02307526 | Trial comparisons |
Papers from its trials25
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005469
GET https://conductscience.org/api/diseases/v1/MONDO_0005469/drugs?page=2